Sol-Gel Technologies (SLGL) files update on SGT-210 Darier Phase 1b

Rhea-AI Filing Summary

Sol-Gel Technologies Ltd. filed a Form 6-K as a foreign private issuer to furnish a press release issued on December 17, 2025. The press release provides an update following unblinding of the company’s Phase 1b study of SGT-210 in Darier Disease.

Exhibit 99.1, which contains the press release (other than its third paragraph), is incorporated by reference into Sol-Gel’s existing Registration Statements on Form S-8 (Registration Nos. 333-223915, 333-270477 and 333-286820) and its Registration Statement on Form F-3 (Registration No. 333-286822).

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the month of December 2025

Commission File Number 001-38367

SOL-GEL TECHNOLOGIES LTD.

(Translation of registrant’s name into English)

7 Golda Meir Street

Ness Ziona 7403650, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒           Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Explanatory Note

On December 17, 2025, Sol-Gel Technologies Ltd. (the “Company”) issued a press release providing an update following unblinding of Phase 1b Study of SGT-210 in Darier Disease

Attached hereto are the following exhibit:

Exhibit 99.1          Press release dated December 17, 2025

Exhibit 99.1 (other than the third paragraph) is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (Registration Nos. 333-223915, 333-270477 and 333-286820) and its Registration Statement on Form F-3 (Registration No 333-286822).

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SOL-GEL TECHNOLOGIES LTD.
Date:  December 17, 2025	By:	/s/ Eyal Ben-Or
		Eyal Ben-Or
		Chief Financial Officer

3

FAQ

What does Sol-Gel Technologies Ltd. (SLGL) report in this Form 6-K?

The Form 6-K reports that Sol-Gel Technologies Ltd. issued a press release on December 17, 2025 providing an update following unblinding of its Phase 1b study of SGT-210 in Darier Disease.

What is the focus of Sol-Gel Technologies' SGT-210 Phase 1b study?

The document states that SGT-210 is being evaluated in a Phase 1b study in Darier Disease, and the press release provides an update following unblinding of this study.

Which exhibit contains the SGT-210 Darier Disease study update for Sol-Gel Technologies (SLGL)?

The update is contained in Exhibit 99.1, described as a press release dated December 17, 2025, attached to the Form 6-K.

How is Exhibit 99.1 used in Sol-Gel Technologies' SEC registration statements?

Exhibit 99.1 (other than its third paragraph) is incorporated by reference into Sol-Gel’s Registration Statements on Form S-8 and its Registration Statement on Form F-3, making the press release part of those registration documents.

Which specific Sol-Gel Technologies registration statements incorporate the SGT-210 press release?

The press release is incorporated into Form S-8 Registration Nos. 333-223915, 333-270477 and 333-286820, and into the Form F-3 Registration No. 333-286822.

Why did Sol-Gel Technologies file this report as a foreign private issuer?

The document is a Form 6-K Report of Foreign Private Issuer, which Sol-Gel Technologies uses to furnish its SGT-210 Phase 1b study press release to the market.